Ironwood Pharma (IRWD) Tops Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Above Consensus

Go back to Ironwood Pharma (IRWD) Tops Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Above Consensus

Ironwood Pharma (IRWD) Surges 12% Following Results/Outlook

February 13, 2019 10:02 AM EST

Ironwood Pharma (NASDAQ: IRWD) is gaining 12% in early following better-than-expected Q4 results and guidance.

... More